drugset / Trial / NCT03752606

Application of Tachosil During Lymphadenectomy

NCT03752606

Phase 4 Completed 50 enrolled Medical University of Lublin Takeda · collab
RandomizedCrossoverSingle-blindTreatment

Summary

The prevention of lymphoceles was assessed using collagen patch coated with the human coagulation factors (TachoSil, Nycomed International Management GmbH, Zurich, Switzerland; NCT Number ICMJE NCT01192022; Other Study ID Numbers ICMJE TC-2402-040-SP; U1111-1130-9121 Registry Identifier: WHO) on 50 consecutive patients with endometrial and cervical cancer stages IB to II who had undergone open hysterectomy and pelvic lymphadenectomy (PL). Methods: Each patient was simultaneously randomized in two groups: as a control (side without Tachosil applied) and study group (side with Tachosil applied). All surgical parameters were collected and patients underwent ultrasound examination on postoperative days 1, 6, and 30, and at the end of treatment.

Timeline

Start
2013-11-29
Primary completion
2014-12-31
Completion
2017-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator TachoSil Other / unclassified Topical